In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Inventiva, with a price target of $26.00. The company’s shares closed yesterday at $5.53.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Rahimi is a 5-star analyst with an average return of 15.4% and a 46.14% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Nektar Therapeutics, and Madrigal Pharmaceuticals.
Currently, the analyst consensus on Inventiva is a Strong Buy with an average price target of $19.00, a 243.58% upside from current levels. In a report released yesterday, Canaccord Genuity also reiterated a Buy rating on the stock with a $20.00 price target.
Based on Inventiva’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $6.46 million and a GAAP net loss of $135.18 million. In comparison, last year the company earned a revenue of $16.54 million and had a GAAP net loss of $55.16 million
Read More on IVA:
Disclaimer & DisclosureReport an Issue
- Buy Rating for Inventiva: Lanifibranor’s Potential as a Foundational MASH Therapy
- Inventiva price target raised to $24 from $20 at H.C. Wainwright
- 3 Best Stocks to Buy Now, 10/02/2025, According to Top Analysts
- Inventiva’s Strategic Focus and Financial Stability Drive Buy Rating Amid Promising Phase 3 Trial Progress
- Inventiva management to meet with Piper Sandler
/AI%20(artificial%20intelligence)/Image%20of%20server%20racks%20in%20modern%20server%20room%20data%20center%20by%20Sashkin%20via%20Shutterstock.jpg)
